Lipocine Reports Positive Interim Safety Results in Phase 3 Trial of Oral PPD Treatment
Lipocine Inc. announced positive interim safety results in its Phase 3 trial for LPCN 1154, an oral treatment for postpartum depression. The Data Safety Monitoring Board recommended the trial continue as planned after reviewing safety data from one-third of the participants. No serious adverse events were reported among the 47 participants who completed dosing. Topline results are expected in Q2 2026.
Lipocine Inc. announced the completion of a scheduled independent Data Safety Monitoring Board (DSMB) review for its ongoing Phase 3 clinical trial evaluating LPCN 1154, an oral brexanolone product candidate for the rapid relief of postpartum depression (PPD). The DSMB recommended that the trial continue as planned without modification after reviewing safety data from approximately one-third of the planned 80 participants. To date, 47 participants have completed dosing with no reported drug-related serious adverse events, dose reductions, discontinuations, excessive sedation, or loss of consciousness. Topline results from the Phase 3 study are expected in the second quarter of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA26803) on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
